Therapy of hepatitis C;Therapie der Hepatitis C

Medizinische Klinik

Volumn 92, Issue 3, 1997, Pages 147-161

  Alscher, Dominik M ^a,b   Bode, J Christian ^a  

^a ROBERT BOSCH GMBH   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT; RIBAVIRIN; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; HEPATITIS C; HUMAN; REVIEW;

HEPATITIS C VIRUS;

EID: 0030992464     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03043273     Document Type: Review

References (127)

1. Alba, R. D., M. Sampietro, S. Fargion, L. Roffi, S. Parma, M, Pozzi, C Nicoli, N. Corbetta, V. Arosio, A. Piperno: Iron stores and virus genotypes in chronic hepatitis C. Relation with alfa- interferon response. Hepatology 22 (1995), 294.
2. Alberti, A , L. Chernello, P. Bonetti, C. Casarin, G. Diodati, L. Cavaletto, D. Cavaletto, M. Frezza, C. Donada, F. Belussi, P. Casarin, G. Pozzato, A. Ruol and the TVVH study group: Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C J Hepatol. 17, Suppl. 3 (1993), S123-S126.
3. Alscher, D. M., J. Ch. Bode: Therapie der akuten und chronischen Virushepatitis C (Non-A-non-B) mit Interferon-Alpha. Med. Klin. 87 (1992), 532-539.
4. Alter, H J.: Clinical, virological and epidemiological basis for the treatment of chronic non-A, non-B hepatitis. J Hepatol. 11 (1990), S19-S25.
5. Alter, H. J.: To C or not to C: These are the questions. Blood 85 (1995), 1681-1695.
6. Andreone, P., A. Gramenzi, C. Cursaro, L. Di Giarnmarino, S. Fiorino, P. Scrivano, A. D'Errico, R. Miniero, M Bernardi, G. Gasbarrini: A randomized controlled trial of IFN-alfa + ketoprofen or IFN-alfa + ribavann in HCV chronic active hepatitis (CAH) non-responderto IFN alfa alone. Hepatology 22 (1995), 119A.
7. Arber, N , M. Moshkowitz, F Konokoff, Z. Halpern, A. Hallak, M. Santo, E. Tiomny, M. Baratz, T. Gilat: Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection. Dig. Dis. Sci 40 (1995), 2431-2433.
8. Ascione, A., M DeLuca, C. Canestrini, L. Amitrano, T. Gigliotti, L. Addano, A Sergio, G. B. Forte, P. Rocco, O Biceglia, D. Faleo, F. Vinelli, E.M. Cela, G. Manno, R. Sabatino, G. Rodinó, G. Raimondo: Three versus six MU interferon (IFN) alfa-2b in the therapy of HCV-related chronic liver disease: Randomized multicenter study. Hepatology 20 (1994), 155A.
9. Attili, A. F., A. Rusticali, M. Varriale, L. Carli, A. M. Repice, F. Calea: The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12 month double-blind, placebo-controlled trial. J. Hepatol. 20 (1994), 315-320.
10. Balart, L. A., R. Perillo, J. Roddenbeny, F. Regenstein, K.-S. Shim, Y. S. C. Shieh, B. Taylor, S. Dash, M. A. Gerber: Hepatitis C RNA in liver of chronic hepatitis C patients before and after Interferon alfa treatment Gastroenterology 104 (1993), 1472-1477.
11. Battochia, A., P. Residori, L. Biti: Durable response to alpha-interferon treatment in patients with chronic hepatitis C. Gut 35, Suppl. 4 (1994), A54.
12. Bellati, G., M. G. Colloredo, L. Roffi, G. Sarraco, D. Tempesta, A. Bellobuono, A. Rho, M. D'Acquino, G. Angeli, G. Idéo, F. Bonino: Prevalence of breakthrough during alpha interferon therapy for chronic hepatitis C. Hepatology 20 (1994) 331A.
13. Bellobuono, A., L. Mondazzi, S. Tempini, G. Bellati, L. Cassarà, M. Lombino, E. Silini, F. Bono, G. Idéo: Efficacy of different regimens of alpha interferon, in chronic hepatitis C and relationship between response and HCV genotyp. J. Hepatol. 21, Suppl. 1 (1994), S 35.
14. Bode, J. Ch., D. M. Alscher, H. Wisser, Ch. Bode: Detection of hepatitis C virus antibodies and hepatitis C virus RNA in patients with alcoholic liver disease. Alcohol and Alcoholism 30 (1995), 97-103.
15. Bonkovsky, H. L., B. D. Clifford, L. J. Smith, C. Allan, B. Banner. High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C - a controlled randomized trial. Dig. Dis. Sci. 41 (1996), 149-154.
16. Boucher, E., H. Jouanolle, P Andre, A. Ruffault, D. Guyader, R. Moirand, B. Turlin, C. Jacquelinet, P. Brissot, Y. Deugnier: Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients Hepatology 21 (1995), 322-327.
17. Booth, J. C. L., G. R. Foster, U. Kumar, R. Galassini, R. D. Goldin, J L. Brown, H. C. Thomas: Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alfa. Gut 36 (1995), 427-432.
18. Bréchot, C., D. Krenisdorf: Genetic variation of the hepatitis C virus (HCV) genome: Random events or a clinically relevant issue? J. Hepatol. 17 (1993), 265-268.
19. Brillanti, S , M Miglioli, L. Barbara: Combination antivital therapy with ribavarin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J. Hepatol. 23, Suppl. 2 (1995), 13-16.
20. Brouwer, J. T., F. Nevens, P. Michielsen, M. L. Hautekeete, R. A. F. M. Chamuleau, M. Adler, J. Delwaide, R. A. Heijtink, S. W. Schalm: What options are left when hepatitis C does not respond to interferon? Placebo-controlled benelux multicentre retreatment trial on ribavann monotherapy versus combination with interferon. J. Hepatol. 24, Suppl. 1 (1994), S17.
21. Camma, C., P. Almasio, A. Craxi: Interferon as treatment for acute hepatitis C - a meta-analysis. Dig. Dis. Sci 41 (1996), 1248-1255.
22. Camps, J., A. Castilla, J. Ruiz, M P. Civeira, J. Prieto: Randomised trial of lymphoblastoid alfa-interferon in chronic hepatitis C. J. Hepatol. 17 (1993), 390-396.
23. Camps, J , N. García, J. I. Riezu-Boj, M.P. Civeira, J. Prieto: Ribavinn in the treatment of chronic hepatitis C unresponsive to alfa Interferon. J. Hepatol 19 (1993), 408-412.
24. Carreno, V., A Quiroga: Biologic response modifiers in chronic hepatitis C. J. Hepatol. 22, Suppl. 1 (1995), 122-126.
25. Causse, X., H. Godinot, M. Chevallier, Ph. Chossegros, F. Zouli, D. Ouzan, J.-P. Heyraud, Th. Fontanges, J. Albrecht, C. Meschievitz, Ch. Trepo: Comparison of 1 or 3 MU of interferonalfa-2b and placebo in patients with chronic Non-A, Non-B hepatitis Gastroenterology 101 (1991), 497-502
26. Causse, X. H. Godinot, D. Ouzan, Ph. Chossegros, M. Chevallier, C. Meschievitz, C. Trépo: Recombinant alpha interferon for chronic non-A non-B hepatitis: Optimal dose and factors associated with favorable response. Hepatology 10 (1989), 643.
27. Chayama, K., A. Tsubota, Y. Arase, S. Saitoh, K. Ikeda, T. Matsumoto, M Hashimoto, M. Kobayashi, M. Kanda, T Monnaga, H Kuniad: Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervanable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C. J. Hepatol. 23 (1995), 648-633.
28. Chernello, L., L. Cavaletto, E. Bernardinello, M. Gutdo, P. Pontisso, A. Alberti: The effect of interferon alfa and ribavarin combination therapy in naive patients with chronic hepatitis C. J. Hepatol 23, Suppl. 2 (1995), 8-12.
29. Chemello, L., P. Bonetti, L. Cavaletto, F. Talato, V. Donadon, P. Casarin, F. Belussi, M. Frezza, F. Noventa, P. Pontisso, L. Benvegnù, C. Casarin, A. Alberti: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 22 (1995), 700-706.
30. Choo, Q.-L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, M. Houghton: Isolation of a cDNA clone derived from a blood-borne Non-A, Non-B viral hepatitis genome. Science 244 (1989), 359-362.
31. Craxi, A., V. DiMarco, O. Lo Iacono, P. Almasio, R. Bruno, C. Cammà, R. Volpes, L. Pagliaro: Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months. J. Hepatol. 24 (1996), 539-546.
32. Craxi, A., O. Lolacono, V. DiMarco, P. Almasio, A. Vaccaro, C. Cammà, C. Fabiano, S. Magrin, P. Simmonds, L. Pagliaro: Community-aquired chronic hepatitis C in an area of high serotyp 1 endemicity: Interferon for 6 or 12 months? Hepatology 20 (1994), 162A.
33. Cutler, D. L.: Pharmacology of interferon. In: Arroyo, V., J. Bosch, J. Rodés: Treatments in hepatlogy. Masson, Barcelone 1995.
34. Davis, G. L., L. A. Balart, E. R. Schiff, K. Lindsay, H. C. Bodenheimer, R. P. Perrilo, W. Carey. I. M. Jacobson, J. Payne, J- L. Dienstag, D. H. Van Thiel, C. Tarnburro, J. Lefkowitch, J. Albrecht, C. Meschievitz, T. J. Ortego, A. Gibas: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. New Engl. J. Med. 32 (1989), 1501-1506.
35. Davis, G. L.: Prediction of response to interferon treatment of chronic hepatitis C. J. Hepatol. 21 (1994), 1-3.
36. Davis, G. L., J. Y. N. Lau: Choice of appropiated end-points of response to interferon therapy in chronic hepatitis C virus infection. J. Hepatol. 22, Suppl. 1 (1995), 110-114.
37. Di Bisceglie, A. M., P. Martin, Ch. Kassianides, M. Lisker-Melman, L. Murray, J. Waggoner, Z Goodman, S. Banks, J. H. Hoofnagle: Recombinant interferon alpha therapy for chronic hepatitis C. New Engl. J. Med. 321 (1989), 1506-1510.
38. Dienstag, J. L.: Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology 85 (1983), 439-462.
39. Diodati, G., P. Bonetti, F. Noventa, C. Casarin, R. Rugge, S. Scaccabarozzi, A. Tagger, L. Pollice, F. Tremolada, C. Davite, G. Realdi, A. Ruol: Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a. Results of a randomized controlled clinical trial Hepatology 19 (1994), 1-5.
40. Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, Y. Ogura, N. Izumi, F. Marumo, C. Sato: Mutations in the nonstructural protein 5a gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New Engl. J. Med. 334 (1996), 77-81.
41. Farrell, G. C., W. G. E. Cooksley, F. J. Dudley, K. Watson: Intensive 6-month course of Interferon treatment for chronic hepatitis C and cirrhosis. Hepatology 22 (1995), 118A.
42. Felaco, F. M., L. Aprea, V. Messina, P. Filippini, E. Sagnelli, F. Picinino: Effect of a 24 month alpha IFN treatment in HCV chronic hepatitis. J. Hepatol. 21, Suppl. 1 (1994), S105.
43. Fernández, I., G. Castellano, F. Canga, F. Colina, A. Fuertes, A. Martin, B. Casis, P. Sanchez, J. A. Sollis: A randomized, comparative study of the long-term effiacy of interferon alfa-2b and IFN alfa-2a for the therapy of chronic hepatitis C J. Hepatol. 21, Suppl. 1 (1994), S26.
44. Fern, C., E. Marzo, G. Longombardo, L. La Civita, F. Lmbardini, D. Giuggioli, R. Vanacore, A. M. Liberati, A. Mazzoni, F. Greco, S. Bombardieri. Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial. Gut Suppl. (1993), S144-S145.
45. Gerber, M. A.: Pathobiologic effects of hepatitis C. J. Hepatol. 22, Suppl. 1 (1995), 83-86.
46. Giostra, F., R. Francesconi, P. Groff, A. Manzin, L Solfroi, F. Lan, G Ballardini, M. Lenzi, M. Clementi, F. B. Bianchi: Wide fluctuation of plasmatic HCV genome levels in serial samples of patients before Interferon treatment. Hepatology 22 (1995), 341A.
47. Gerken, G., G. Teuber, B. Goergen, K. H. Meyer zurn Büschenfelde: Interferon-alpha retreatment in chronic hepatitis C. J. Hepatol. 22, Suppl. 1 (1995), 118-121.
48. Glück, T., H. Dürk, I. Kötter, C. Zimmermann, J. G. Saal: Kryoglobulinärnie bei chronischer Hepatitis C. Med. Klin. 90 (1995), 674-680.
49. Gonzalez-Peralta, R. P., G. L. Davis, J. Y. Lau: Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J. Hepatol. 21 (1994), 255-259.
50. Goeser, T., U. Töx, H. M. Müller, J. C. Arnold, L. Teilmann: Bedeutung der Genotypen bei chronischer Hepatitis-C-Virusinfektion und Hepatitis-C-Virus-bedingter Leberzirrhose in Deutschland. Dtsch. med. Wschr. 120 (1995), 1070-1073.
51. Gomez-Rubio, M., J. C. Portes, I. Castillo, J. A. Quiroga, A. Moreno, V. Carreno: Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J. Hepatol. 11, Suppl. 1 (1990), S63-S67.
52. Gordon, S. C., V. P. Kodali, A. L. Silverman, C. F. Dmuchowski, M. S. Urdea, C. S. Chan, J. C. Wilber: Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. Amer. J. Gastroent. 89 (1994), 1458-1461.
53. Gumber, S. C., S. Chopra: Hepatitis C: A multifaceted disease. Ann. intern. Med. 123 (1995), 615-620.
54. Haber, M. M., A. B. West, A. D. Haber, A. Reuben: Relationship of arninotransferases to liver histological status in chronic hepatitis C. Amer. J. Gastroent. 90 (1995), 1250-1257.
55. Hakozaki, Y., T. Shirahama, M. Katou, K. Nakagawa, K. Oba, K. Mitamura: A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. Amer. J. Gastroent. 90 (1995), 1246-1249.
56. Hatanaka, Y., Y. Yamashita, M. Takahashi, Y. Koga, R. Saito, K. Nakashima, J. Urata, M. Miyao: Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter managment. Radiology 195 (1995), 747-752.
57. Healey, C. J., R. W. G. Chapman, K. A. Fleming: Liver histology in hepatitis C infection: a comparsion between patients with persistently normal or abnormal transaminases. Gut 37 (1995), 274-278.
58. Hoofnagle, J. H., D. Lau: Chronic viral hepatitis - benefits of current therapies New Engl J. Med. 334 (1996), 1470-1471.
59. Hoofnagle, J. H., K. P. Mullen, B. D. Jones, V. Rustgi, A. DiBisceglie, M. Peters, J. G. Waggoner, Y. Park, E. A. Jones: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon. New Engl. J. Med. 315 1986), 1575-1578.
60. Hoofnagle, J. H., H. S. Conjeevaram, D. E. Kleiner, D. Lau, A. M. DiBisceglie: Two year course of ribavarin for chronic hepatitis C. Hepatology 22 (1995), 48.
61. Hopf, U., T. Berg, V. König, S. Küther, H.-G. Heuft, H. Lobeck: Treatment of chronic hepatitis C with interferon alpha: long-term folow-up and prognostic relevance of HCV genotypes. J Hepatol. 24, Suppl. 2 (1996), 67-73.
62. Hwang, S.-J., S.-D. Lee, C.-Y. Chan, R.-H. Lu, K.-J. Lo: A randomized controlled trial of interferon alfa-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J. Hepatol. 21 (1994), 831-836.
63. Ideo, G., G. Bellati, E. Pedraglio, G. Alfieri: Recombinant alpha 2a interferon (r-IFN), lymphoblastoid alpha interferon (1-IFN) or no treatment tor nonA nonB chronic active hepatitis (CAH): A prospective randomized controlled trial. Hepatology 10 (1989), 637.
64. Ideo, G., G. Bellati, E. Pedraglio, G. Leandro: One year of therapy of nonA, nonB C chronic hepatitis with recombinant alfa2a interferon (r-IFN) or lymphoblastoid alfa interferon (1-FN). J. Hepatol. 11, Suppl. 2 (1990), 122.
65. Iino, S , K. Hino, T. Kuroki, H. Suzuki, S. Yamamoto. Treatment of chronic hepatitis C with high-dose interferan alfa-2b. Dig. Dis. Sci. 38 (1993), 612-618.
66. Jacyna, M. R., M. G. Brooks, R. H. T. Loke, J. Main, I. M. Murray-Lyon, H. C. Thorns: Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis. Brit. med. J. 298 (1989), 80-82
67. Janssen, H. L A , J T. Brouwer, R C van der Mast, S. W. Schalin: Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J. Hepatol. 21 (1994), 241-243.
68. Kagawa, T., T. Monzane, H. Saito, S. Miyaguchi, S. Tsunematsu, S. Tada, F. M. Guevara, N. Kumagi, K. Tsuchimoto, T. Watanabe, M. Tsuchiya: A randomized, controlled trial of weekly administration of lymphoblastoid Interferon in patients with chronic hepatitis C. J. Hepatol. 17 (1993), 91-96.
69. Kakumu, S , M. Arao, K. Yoshioka, H. Hayashi, A. Kusakabe, H. Hirofuji, M. Kawabe: Recombinant human alpha-interferon therapy for chronic non-A, non-B hepatitis: Second repon Amer. J. Gastroent. 85 (1990), 655-659.
70. Kanazawa, Y., N. Hayashi, E. Mita, T. Li, H. Hagiwara, A. Kasahara, H. Fusamoto, T. Kamada: Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20 (1994), 1121-1130.
71. Kao, J.-H., P.-J. Chen, M.-Y. Lai, T-H. Wang, D.-S. Chen: Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis. J. infect. Dis. 172 (1995), 261-264.
72. Kashara, A., N. Hayashi, N. Hiramatsu, M. Oshit, H. Hagiwara, K. Katayama, M. Kato, M. Masuzawa, H. Toshihara, V. Kishida, Y. Shimizu, A. Inoue, H. Fusamoto, T. Kamada: Ability of prolonged interferon treatment to supress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 21 (1995), 291-297.
73. Kins, G., E. Papagianni, D. Tzilves, F. Kordits, G. Kokozidis: Co-administration of granulocyte colony-stimulating factor allows completion of interferon therapy in chronic viral hepatitis with neutropenia. Hepatology 20 (1994), 171A.
74. Kobayashi, Y., S. Watanabe, M. Konishi, M. Yokoi, R. Kakehashi, M. Kaito, M. Kondo, Y. Hayashi, T. Jomori, S. Suzuki: Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-alfa. Hepatology 18 (1993), 1319-1325.
75. Kurosaki, M., N. Enomoto, F. Marumo, C. Sato: Rapid sequencevariation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology 18 (1993), 1293-1299.
76. Lam, N. P , T E Wiley, D. R. Gretch, D. L. Pitrak, T. J. Layden: Dose-dependent acute reduction of genotyp 1 hepatitis C virus (HCV) with alpha-interferon (IFN). Hepatology 22 (1995), 172A.
77. Lampertico, P., M. Rumi, R. Romeo, A. Craxi, R. Soffredini, D. Biassoni, M. Colombo: A multicenter randomized controlled trial of recombinant interferon-alfa 2b in patients with acute transfusion-associated hepatitis C. Hepatology 19 (1994), 19-22.
78. Lin, R. M., P. Schoeman, J. Craig, J. Mac Donald, R. G. Batey, G C. Farrell: Randomized controlled trial of interferon alpha 2 b for chronic active hepatitis Non A, Non B: Biochemical and histological evidence of remission. Hepatology 10 (1989), 646.
79. Livraghi, T., L. Bolondi, L. Buscarini, M. Cottone, A. Mazziotti, A. Morabito, G. Totzilli and the Italian cooperative HCC study group: No treatment, resection and ethanol injection in hepatocellular carcinome: a retrospektive analysis of survival in 391 patients with cirrhosis. J. Hepatol. 22 (1995), 522-526.
80. Maier, K.-P : Behandlung der chronischen Virushepatitis mit Azetylsalizylsäure. Schweiz, med, Wschr, 125 (1995), 755-757.
81. Makris, M., F. E. Preston, D. R. Triger, J. C. E. Under-wood, L. Westlake, M. J Adelman: Interferon alfa for chronic hepatitis C in haemophiliacs. Gut Suppl. (1993), S121-S123.
82. Marcellin, P., N. Boyer, E. Giostra, C. Degott, F. Degos, H. Copperé, P Calès, P. Couzigou, M. Martinot, M. A. Loriot, J.-P. Bernhamou: Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis. A multicenter randomized controlled trial from France. Hepatology 13 (1991), 393-397.
83. Martinot-Peignoux, M , P. Marcellin, M. Pouteau, C Castelau, N. Boyer, M. Poliquin, C. Degott, I. Descombes, V. Le Breton, V. Milotova, J. P. Benhamou, S. Erlinger: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotyp are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22 (1995), 1050-1056.
84. Matsumoto, A , E. Tanaka, T. Suzuki, H. Ogata, K. Kiyosawa: Viral and host factors that contribute to efficacy of interferon-alfa-2a therapy in patients with chronic hepatitis C. Dig. Dis Sci. 39 (1994), 1273-1280.
85. Mazella, G., E. Accogli, S. Sottili, D. Festi, M. Orsini, A. Salzetta, V. Novelli, A. Cipolla, C. Babbri, A. Pezzoli, E. Roda: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J. Hepatol, 24 (1996), 141-147.
86. Métreau, J. M.: Results of long term in̄terferon treatment in non A non B/C chronic active hepatitis Gut Suppl. (1993), S112-S113.
87. Misiarti, R.., P. Bellavita, D. Fenili, O. Vican, D. Marchesi, P. L. Sironi, P. Zilio, A. Vernocchi, M. Massazza, G. Vendramin, E. Tanzi, A. Zanetti: Interferon Alpha-2a therapy in cryoglobulinemia associated with hepatitis C virus. New Engl. J. Med. 330 (1994), 751-756.
88. Mita, E., N. Hayashi, H. Hagiwara, K. Ueda, Y. Kanazawa, A. Kasahara, H. Fusamoto, T. Kamada: Predicting interferon therapy efficiacy from hepatitis C virus genotype and RNA titer. Dig. Dis. Sci. 39 (1994), 977-982.
89. Moribe, T., N. Hayashi, Y. Kanazawa, E. Mita, H. Fusamoto, M. Negi, T. Kaneshige, H. Igirni, T. Kamada, K. Uchida: Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 108 (1995), 789-795.
90. Müller, R., R. Baumgarten, R. Markus, K. H. Beckh, K. Loeschke, W. Stremmel, C. Niederau, K.-H. Wiedmann, P. Weber: Long-term treatment with low doses of interferon alfa-2b (rIFNa2b) in patients with chronic non-A, non-B (NANB) hepatitis. Data of a multicenter randomized prospectively controlled trial. J. Hepatol. 11, Suppl. 2 (1990), 184.
91. Naito, M., N. Hayashi, T. Moribe, H. Hagiwara, E. Mita, V. Kanazawa, A. Kasahara, H. Fusamoto, T. Kamada: Hepatitis C viral quasispecies in hepatitis C virus carr̄ieres with normal liver enzymes and patients with type C chronic liver disease. Hepatology 22 (1995), 407-412.
92. Nakazawa, T., N. Kato, S. Ohkoshi, A. Shibuya, K. Shimotohno: Characterization of the 5′noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment. J. Hepatol. 20 (1994), 623-629.
93. Nishiguchi, S., T. Kuroki, S. Nakatani, H. Morimoto, T. Takeda, S. Nakajima, S. Shiomi, S. Seki, K. Kobayashi, S. Otni. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346 (1995), 1051-1055.
94. Ohlen, J., J. M. Liegl, H. Selmair: Die Langzeitprognose chronischer Virus B- und Virus C-Hepatitiden. Leber Magen Darm 25 (1995), 205-210.
95. Okada, S.-I., Y. Akahane, H. Suzuki, H. Okamoto, S. Mishiro: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16 (1992), 619-624.
96. Okanoue, T., S. Sakamoto, Y. Itoh, M. Minami, Y. Yasui, M. Sakamto, M. Nishioji, K. Kashima: Side efects of high-dose interferon therapy for chronic hepatitis C-mass study. Hepatology 22 (1995), 118A.
97. Olynyk, J. K., K. R. Reddy, A. M. DiBisceglie, L. J. Jeffers, T. I. Parker, J. L. Radick, E. R. Schiff, B. R. Bacon: Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitus C. Gastroenterology 108 (1995), 1104-1109.
98. Pagliaro, L., A. Craxi, C. Cammaá, F. Tiné, V. Di Marco, O. Lo Iacono, P. Almasío; Interferon-alpha for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 19 (1994), 820-828.
99. Papa, D., A. Gianmarino, A. Rebuttato,. G. Orlando: Treatment of chronic hepatitis with interferon. J. Hepatol. 21, Suppl. 1 (1994), S120.
100. Picciotto, A., G. Varagona, F. Valle, D. A. Coviello, G. Lapertosa, G. Celle: Interferon therapy in chronic hepatitis C. J. Hepatol. 17 (1993), 359-363.
101. Poynard, T., P. Bedossa, M. Chevallier, P. Mathurin, C. Lemonnier, C. Trepo, P. Couzigou, J. L. Payen, M. Sajus, J M. Costa, M. Vidud, J. C. Chaput: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. New Engl. J Med. 332 (1995), 1457-1462.
102. Realdi, G., G. Diodati, P. Bonetti, S. Scaccabarozzi, A. Alberti, A. Ruol: Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial. J. Hepatol. 11 (1990), S68-S71.
103. Reichard, O., U. Foberg, A. Frydén, L. Mattsson, G. Norkrans, A. Sönnerborg, R. Wejstal, Z-B. Yun, O. Weiland: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha-2b for 60 weeks. Hepatology 19 (1994), 280-285.
104. Roffi, L., G. C. Mels, G. Antonelli, G. Bellati, F. Panizzuti, A. Pipemo, M. Pozzi, D. Ravizza, G. Angeli, F. Dianzani, G. Mancia: Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology and managment. Hepatology 21 (1995), 645-649.
105. Rossini, A., A. Ravaggi, L. Biasi, G. B. Gazzola, E. Agostínelli, M. Puoti, E. Radaeli, E. Cariani: HCV infection with normal ALT and chronic hepatitis: Long-term follow-up and genomic characterization of HCV-RNA. Hepatology 20 (1994), 242A.
106. Saez-Royuela, F., J. C. Porres, A. Moreno, I. Castillo, G. Martinez, F. Galiana, V. Carreno: High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: A randomized, controlled trial. Hepatology 13 (1991), 327-331.
107. Saracco, G., F. Rosina, M. R. Torrani Cerenzia, V. Lattore, L. Chiandussi, V. Gallo, R. E. Petrino, A. G. De Miheli, E. Donegani, A. Slinas, A. Deplano, A. Tocco, P. Cossu, C. Pintu, E. David, G. Mazzucco, G. Verrne, M. Rizzetto: A randomized controlled trial of Interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J. Hepatol. 11 (1990), S43-S49.
108. Saracco, G., F. Rosina, M. L. Abate, L. Chiandusi, V. Gallo, E. Cerutti, A. Di Napoli, A. Solinas, A. Deplano, A. Tocco, P. Cossu, D. Chien, G. Kuo, A. Polito, A. J. Weiner, M. Houghton, G. Verme, F. Bonino, M. Rizzetto: Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alfa-2b Hepatology 18 (1993), 1300-1305
109. Schvarz, R., O. Weiland, R. Wejstal, G. Norkrans, A. Fryden, U. Foberg: A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand. J. infect. Dis. 21 (1989), 617-625.
110. Shibata, M., T. Kumada, M. Yamada, S. Nakano, T. Kudo, T. Morishima: Efects of interferon-alpha on serum hepatitis C virus in patients with chronic hepatitis C. Dig. Dis. Sci. 38 (1993), 608-611.
111. Shindo, M., K. Arai, Y. Sokawa, T. Okuno: The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 22 (1995), 418-425.
112. Shindo, M., A. M. DiBisceglie, L. Cheung et al.: Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann. intern. Med. 115 (1991), 700-704.
113. Simmonds, P.: Variability of hepatitis C virus. Hepatology 21 (1995), 570-583.
114. Simmonds, P., J. Mellor, A. Craxi, J.-M. Sanchez-Tapias, A. Alberti, J. Prieto, M. Colombo, M. G. Rumi, O. Lo Iacno, S. Ampurdanes-Mingall, X. Forns-Bernhardt, L. Chemello, M-P. Civeira, C. Frost, G. Dusheiko: Epidemiological, clinical and therapeutic associations of hepatitis C types in Western European patients. J. Hepatol. 24 (1996), 517-524.
115. Takada, A., M. Tsutsumi: Efficacy of a combination therapy with Interferon and ofloxacin in chronic type C hepatitis. Hepatology 20 (1994), 170A.
116. Takahashi, M., G. Yamada, R. Miyamoto, T. Doi, H. Endo, T. Tsuji: Natural course of chronic hepatitis C. Amer. J. Gastroent. 88 (1993), 240-243.
117. Takano, S., Y. Ito, O. Yokosuka, M. Ohto, K. Uchiumi, K. Hirota, M. Omata: A multicenter randomized controled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 20 (1994), 558-564.
118. Thomson, B. J., A. L. Lever, M. Doran, A. D. B. Webster: Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gamagobulin replacement therapy. Lancet (1987), 539-541.
119. Tong, M. J., N. S. El-Farra, A. R. Rekes, R. L. Co: Clinical outcomes after transfusion-associated hepatitis C. New Engl. J. Med. 332 (1995), 1463-1466.
120. Van Thiel, D. H., P. Caraceni, P. J. Molloy, T. Hassanein, R. J. Kania, A. Gurakar, L. Friedlander: Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: The role of interferon Alfa-2b therapy. J. Hepatol. 23 (1995), 503-508.
121. Yamada, G., M. Takatani, F. Kishi, M. Takahashi, T. Doi, T. Tsuji, S. Shin, M. Tanno, M. S. Urdea, J. A. Kolberg: Efficacy of interferon Alfa therapy in chronic hepatitis C patients depends primarly on hepatitis C virus RNA level. Hepatology 22 (1995), 1351-1354.
122. Yano, M., S. Kakumu, H. Hayashi, T. Takikawa, N. Nishimura: Phlebotomy followed by alfa-interferon therapy in patients with chronic hepatitis C. Hepatology 22 (1995), 51.
123. Yokosuka, O., F. Imazeki, M. Tagawa, T. Ehata, T. Seta, K. Fujiwara, A. Honda, M. Ohto, M. Omata: Spontaneous termination of HCV viremia is a rare event in chronic type C hepatitis. Hepatology 20 (1994), 253A.
124. Yokosuka, O., N. Kato, K. Hosoda, Y. Ito, F. Iazeki, M. Ohto, M. Omata: Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut 37 (1995), 721-726.
125. Yuki, N., N. Hayashi, A. Kasahara, H. Hagiwara, T. Takehara, M. Oshita, K. Katayama, H. Fusamoto, T. Kamada: Pretreatment viral load and response to prolonged interferon-aifa course for chronic hepatitis C. J. Hepatol. 22 (1995), 457-463.
126. Zachoval, R., J. Abb, V. Zachoval, J. Eisenburg, G. R. Pape, G. Paumgartner, T. Deinhardt: Interferon alpha in hepatitis type B and non-A, non-B Defective production by peripheral blood mononuclear cells in chronic infection and development of serum interferon in acute disease. J. Hepatol. 6 (1988), 364-368.
127. Zoulim, F., C. Trepo: Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications. J. Hepatol. 21 (1994), 142-144.